Blueprint Medicines Corp (NASDAQ:BPMC) insider Kate Haviland sold 6,775 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $74.93, for a total transaction of $507,650.75. Following the completion of the transaction, the insider now owns 12,649 shares of the company’s stock, valued at $947,789.57. The sale was disclosed in a filing with the SEC, which is available at this link.
Blueprint Medicines Corp (NASDAQ:BPMC) opened at $82.55 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines Corp has a 12 month low of $32.43 and a 12 month high of $92.00.
Several research analysts have commented on BPMC shares. ValuEngine lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Raymond James Financial set a $82.00 price objective on shares of Blueprint Medicines and gave the stock a “buy” rating in a report on Sunday, December 10th. Wedbush restated an “outperform” rating and issued a $82.00 price objective (up from $70.00) on shares of Blueprint Medicines in a report on Monday, November 6th. BidaskClub lowered shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research lowered shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.20.
ILLEGAL ACTIVITY WARNING: This report was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/markets/insider-selling-blueprint-medicines-corp-bpmc-insider-sells-6775-shares-of-stock/1885586.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.